You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

primary mediastinal large B-cell lymphoma (PMBCL)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

Active, not recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • DISEASE
  • (no location specified)
May 4, 2023

Primary Mediastinal Large B-cell Lymphoma With CNS Involvement

Recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • Milan, Italy
      Ospedale San Raffaele
    Aug 29, 2023

    Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

    Not yet recruiting
    • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
    • +5 more
    • Boston, Massachusetts
    • +1 more
    Jun 28, 2023

    Large B-cell Lymphoma, DLBCL, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial (Epcoritamab)

    Available
    • Large B-cell Lymphoma
    • +4 more
    • Epcoritamab
    • (no location specified)
    Feb 16, 2023

    Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Boston (CD79b-19 CAR T cells,

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • +9 more
    • CD79b-19 CAR T cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Sep 6, 2023

    Bio-CAR-T BS Study

    Recruiting
    • Diffuse Large B Cell Lymphoma (DLBCL)
    • +2 more
      • Brescia, Italy
        ASST Spedali Civili di Brescia
      May 5, 2022

      Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • +5 more
      • La Jolla, California
      • +7 more
      Aug 25, 2023

      Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL) Trial in

      Recruiting
      • Diffuse Large-Cell Lymphoma
      • +3 more
      • Pneumococcal conjugate vaccine (PCV13)
      • CD19 targeted CAR T Cell Therapy
      • Tampa, Florida
        Moffitt Cancer Center
      May 31, 2022

      Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day

      Recruiting
      • Non Hodgkin Lymphoma (NHL)
      • +6 more
      • 8/12-Day Production of Car-T Cells
      • +2 more
      • Milwaukee, Wisconsin
        Medical College of Wisconsin and Froedtert Hospital
      Jul 1, 2022

      Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma Trial in Duarte, Nashville, Houston

      Active, not recruiting
      • Anaplastic Large Cell Lymphoma
      • +4 more
      • Duarte, California
      • +3 more
      Jul 21, 2022

      CAR T Cell Therapy Related Cardiovascular Outcomes

      Recruiting
      • Cardiovascular Diseases
      • +7 more
        • London, United Kingdom
          University College London Hospitals
        Nov 18, 2021

        Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

        Not yet recruiting
        • Refractory Aggressive B-cell Lymphomas
        • +12 more
        • Boston, Massachusetts
        • +1 more
        Oct 13, 2022

        Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) Trial in Seoul (CRC01,

        Recruiting
        • Relapsed Large B-cell Lymphoma
        • +5 more
        • CRC01
        • +2 more
        • Seoul, Korea, Republic of
          Samsung Medical Center
        Apr 29, 2021

        Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial in Worldwide (Pembrolizumab)

        Active, not recruiting
        • Hodgkin's Lymphoma
        • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
        • Pembrolizumab
        • Torrance, California
        • +26 more
        Oct 20, 2022

        Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos Trial in Shanghai (Zanubrutinib, Tislelizumab)

        Recruiting
        • Primary Mediastinal Large B Cell Lymphoma
        • EBV-Positive DLBCL, Nos
        • Shanghai, Shanghai, China
          Ruijin Hospital
        Mar 29, 2021

        Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) Trial in

        Not yet recruiting
        • Classical Hodgkin Lymphoma
        • +2 more
        • Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
        • Ancona, Italy
        • +39 more
        Jun 28, 2023

        Primary Mediastinal Large B-Cell Lymphoma (PMBCL) Trial in China (LP002)

        Not yet recruiting
        • Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
        • Beijing, Beijing, China
        • +6 more
        Oct 19, 2020

        Cardiovascular Events Among Adults Relapsed or Refractory

        Recruiting
        • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
        • +9 more
        • Electronic Health Record Review
        • Houston, Texas
          M D Anderson Cancer Center
        Dec 5, 2022

        Communication Training Intervention for Large B-Cell Lymphoma

        Recruiting
        • Lymphoma, B-Cell
        • +5 more
        • Hematolo-GIST Training
        • Participants Appointment
        • New York, New York
        • +2 more
        Jul 3, 2023

        Recurrent DLBCL, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma Trial in Duarte (Biopsy,

        Not yet recruiting
        • Recurrent Diffuse Large B-Cell Lymphoma
        • +11 more
        • Biopsy
        • +5 more
        • Duarte, California
          City of Hope Medical Center
        Jan 3, 2023

        Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

        Not yet recruiting
        • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
        • +21 more
        • Biopsy
        • +8 more
        • Columbus, Ohio
          Ohio State University Comprehensive Cancer Center
        Apr 7, 2023

        Lymphoma, B-Cell Trial in Japan (Pembrolizumab)

        Active, not recruiting
        • Lymphoma, B-Cell
        • Nagoya, Aichi, Japan
        • +8 more
        Aug 18, 2022

        Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,

        Active, not recruiting
        • Hematopoietic and Lymphoid Cell Neoplasm
        • +8 more
        • Anakinra
        • +3 more
        • Houston, Texas
          M D Anderson Cancer Center
        Aug 22, 2022

        Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

        Recruiting
        • Recurrent Diffuse Large B-Cell Lymphoma
        • +8 more
        • Seattle, Washington
          Fred Hutch/University of Washington Cancer Consortium
        Dec 30, 2022

        Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

        Not yet recruiting
        • Diffuse Large B-cell Lymphoma
        • (no location specified)
        Mar 9, 2023